239 related articles for article (PubMed ID: 26312880)
21. Impaired up-regulation of polo-like kinase 2 in B-cell chronic lymphocytic leukaemia lymphocytes resistant to fludarabine and 2-chlorodeoxyadenosine: a potential marker of defective damage response.
de Viron E; Knoops L; Connerotte T; Smal C; Michaux L; Saussoy P; Vannuffel P; Beert E; Vekemans MC; Hermans C; Bontemps F; Van Den Neste E
Br J Haematol; 2009 Dec; 147(5):641-52. PubMed ID: 19764992
[TBL] [Abstract][Full Text] [Related]
22. Investigation of switch from ATM to ATR signaling at the sites of DNA damage induced by low and high LET radiation.
Saha J; Wang M; Cucinotta FA
DNA Repair (Amst); 2013 Dec; 12(12):1143-51. PubMed ID: 24238855
[TBL] [Abstract][Full Text] [Related]
23. DNA-PK, ATM and MDR proteins inhibitors in overcoming fludarabine resistance in CLL cells.
Svirnovski AI; Serhiyenka TF; Kustanovich AM; Khlebko PV; Fedosenko VV; Taras IB; Bakun AV
Exp Oncol; 2010 Dec; 32(4):258-62. PubMed ID: 21270755
[TBL] [Abstract][Full Text] [Related]
24. Prognostic significance of ATM and TP53 deletions in Chinese patients with chronic lymphocytic leukemia.
Xu W; Li JY; Wu YJ; Yu H; Shen QD; Li L; Fan L; Qiu HX
Leuk Res; 2008 Jul; 32(7):1071-7. PubMed ID: 18035414
[TBL] [Abstract][Full Text] [Related]
25. pRAD50: a novel and clinically applicable pharmacodynamic biomarker of both ATM and ATR inhibition identified using mass spectrometry and immunohistochemistry.
Jones GN; Rooney C; Griffin N; Roudier M; Young LA; Garcia-Trinidad A; Hughes GD; Whiteaker JR; Wilson Z; Odedra R; Zhao L; Ivey RG; Howat WJ; Harrington EA; Barrett JC; Ramos-Montoya A; Lau A; Paulovich AG; Cadogan EB; Pierce AJ
Br J Cancer; 2018 Nov; 119(10):1233-1243. PubMed ID: 30385821
[TBL] [Abstract][Full Text] [Related]
26. DNA-dependent protein kinase is a therapeutic target and an indicator of poor prognosis in B-cell chronic lymphocytic leukemia.
Willmore E; Elliott SL; Mainou-Fowler T; Summerfield GP; Jackson GH; O'Neill F; Lowe C; Carter A; Harris R; Pettitt AR; Cano-Soumillac C; Griffin RJ; Cowell IG; Austin CA; Durkacz BW
Clin Cancer Res; 2008 Jun; 14(12):3984-92. PubMed ID: 18559621
[TBL] [Abstract][Full Text] [Related]
27. Concepts of Chronic Lymphocytic Leukemia Pathogenesis: DNA Damage Response and Tumor Microenvironment.
Frenzel LP; Reinhardt HC; Pallasch CP
Oncol Res Treat; 2016; 39(1-2):9-16. PubMed ID: 26889681
[TBL] [Abstract][Full Text] [Related]
28. ATR inhibitor AZD6738 increases the sensitivity of colorectal cancer cells to 5‑fluorouracil by inhibiting repair of DNA damage.
Suzuki T; Hirokawa T; Maeda A; Harata S; Watanabe K; Yanagita T; Ushigome H; Nakai N; Maeda Y; Shiga K; Ogawa R; Mitsui A; Kimura M; Matsuo Y; Takahashi H; Takiguchi S
Oncol Rep; 2022 Apr; 47(4):. PubMed ID: 35191521
[TBL] [Abstract][Full Text] [Related]
29. Targeting the p53 Pathway in CLL: State of the Art and Future Perspectives.
Kwok M; Agathanggelou A; Davies N; Stankovic T
Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572908
[TBL] [Abstract][Full Text] [Related]
30. DNA Damage Response Inhibitor Combinations Exert Synergistic Antitumor Activity in Aggressive B-Cell Lymphomas.
Restelli V; Lupi M; Chilà R; Vagni M; Tarantelli C; Spriano F; Gaudio E; Bertoni F; Damia G; Carrassa L
Mol Cancer Ther; 2019 Jul; 18(7):1255-1264. PubMed ID: 31064869
[TBL] [Abstract][Full Text] [Related]
31. Mutated and non-mutated TP53 as targets in the treatment of leukaemia.
Nahi H; Selivanova G; Lehmann S; Möllgård L; Bengtzen S; Concha H; Svensson A; Wiman KG; Merup M; Paul C
Br J Haematol; 2008 May; 141(4):445-53. PubMed ID: 18341636
[TBL] [Abstract][Full Text] [Related]
32. Therapeutic targeting of a robust non-oncogene addiction to PRKDC in ATM-defective tumors.
Riabinska A; Daheim M; Herter-Sprie GS; Winkler J; Fritz C; Hallek M; Thomas RK; Kreuzer KA; Frenzel LP; Monfared P; Martins-Boucas J; Chen S; Reinhardt HC
Sci Transl Med; 2013 Jun; 5(189):189ra78. PubMed ID: 23761041
[TBL] [Abstract][Full Text] [Related]
33. Rare germline ATM variants of uncertain significance in chronic lymphocytic leukaemia and other cancers.
Petrackova A; Savara J; Turcsanyi P; Gajdos P; Papajik T; Kriegova E
Br J Haematol; 2022 Nov; 199(3):371-381. PubMed ID: 36029002
[TBL] [Abstract][Full Text] [Related]
34. Detection of p53 dysfunction by flow cytometry in chronic lymphocytic leukaemia.
Carter A; Lin K; Sherrington PD; Pettitt AR
Br J Haematol; 2004 Nov; 127(4):425-8. PubMed ID: 15521919
[TBL] [Abstract][Full Text] [Related]
35. FAM135B sustains the reservoir of Tip60-ATM assembly to promote DNA damage response.
Zhang K; Wu Q; Liu W; Wang Y; Zhao L; Chen J; Liu H; Liu S; Li J; Zhang W; Zhan Q
Clin Transl Med; 2022 Aug; 12(8):e945. PubMed ID: 35979619
[TBL] [Abstract][Full Text] [Related]
36. p53 and ATM/ATR regulate 7,12-dimethylbenz[a]anthracene-induced immunosuppression.
Gao J; Mitchell LA; Lauer FT; Burchiel SW
Mol Pharmacol; 2008 Jan; 73(1):137-46. PubMed ID: 17925458
[TBL] [Abstract][Full Text] [Related]
37. Reevaluation of ATR signaling in primary resting chronic lymphocytic leukemia cells: evidence for pro-survival or pro-apoptotic function.
Beyaert M; Starczewska E; Pérez ACG; Vanlangendonck N; Saussoy P; Tilman G; De Leener A; Vekemans MC; Van Den Neste E; Bontemps F
Oncotarget; 2017 Aug; 8(34):56906-56920. PubMed ID: 28915641
[TBL] [Abstract][Full Text] [Related]
38. Mitoxantrone in combination with an inhibitor of DNA-dependent protein kinase: a potential therapy for high risk B-cell chronic lymphocytic leukaemia.
Elliott SL; Crawford C; Mulligan E; Summerfield G; Newton P; Wallis J; Mainou-Fowler T; Evans P; Bedwell C; Durkacz BW; Willmore E
Br J Haematol; 2011 Jan; 152(1):61-71. PubMed ID: 21083655
[TBL] [Abstract][Full Text] [Related]
39. Targeting ATR as Cancer Therapy: A new era for synthetic lethality and synergistic combinations?
Bradbury A; Hall S; Curtin N; Drew Y
Pharmacol Ther; 2020 Mar; 207():107450. PubMed ID: 31836456
[TBL] [Abstract][Full Text] [Related]
40. Studying the cerebellar DNA damage response in the tissue culture dish.
Tzur-Gilat A; Ziv Y; Mittelman L; Barzilai A; Shiloh Y
Mech Ageing Dev; 2013 Oct; 134(10):496-505. PubMed ID: 23583690
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
